Active, not recruitingPhase 3NCT05043090
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
Studying Papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Toni Choueiri, M.DDana-Farber Cancer Institute
- Intervention
- savolitinib(drug)
- Enrollment
- 148 target
- Eligibility
- 18-130 years · All sexes
- Timeline
- 2021 – 2025
Study locations (30)
- Research Site, Boston, Massachusetts, United States
- Research Site, New York, New York, United States
- Research Site, Buenos Aires, Argentina
- Research Site, CABA, Argentina
- Research Site, Ciudad Autonoma Buenos Aires, Argentina
- Research Site, Ciudad Autónoma Buenos Aires, Argentina
- Research Site, Córdoba, Argentina
- Research Site, La Plata, Argentina
- Research Site, Rosario, Argentina
- Research Site, San Miguel de Tucumán, Argentina
- Research Site, Box Hill, Australia
- Research Site, Macquarie University, Australia
- Research Site, St Leonards, Australia
- Research Site, Belo Horizonte, Brazil
- Research Site, Brasília, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05043090 on ClinicalTrials.govOther trials for Papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.